Jennison Associates LLC Buys 65,945 Shares of Henry Schein, Inc. (HSIC)
Jennison Associates LLC grew its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 12.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 615,962 shares of the company’s stock after purchasing an additional 65,945 shares during the period. Jennison Associates LLC owned about 0.39% of Henry Schein worth $50,503,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. YorkBridge Wealth Partners LLC boosted its position in Henry Schein by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock worth $104,000 after purchasing an additional 28 shares in the last quarter. Sun Life Financial INC boosted its position in Henry Schein by 8,185.7% in the 2nd quarter. Sun Life Financial INC now owns 580 shares of the company’s stock worth $106,000 after purchasing an additional 573 shares in the last quarter. Lee Financial Co purchased a new stake in Henry Schein in the 2nd quarter worth approximately $161,000. Acrospire Investment Management LLC boosted its position in Henry Schein by 150.0% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the company’s stock worth $183,000 after purchasing an additional 600 shares in the last quarter. Finally, HM Payson & Co. purchased a new stake in Henry Schein in the 2nd quarter worth approximately $204,000. Institutional investors and hedge funds own 53.07% of the company’s stock.
Several equities research analysts have commented on the company. Leerink Swann restated a “market perform” rating and issued a $77.00 price objective (down previously from $87.50) on shares of Henry Schein in a research report on Tuesday, November 7th. Zacks Investment Research downgraded Henry Schein from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Stifel Nicolaus reduced their target price on Henry Schein from $89.00 to $77.00 and set a “hold” rating for the company in a research note on Tuesday, November 7th. Royal Bank Of Canada reduced their target price on Henry Schein from $91.00 to $82.00 and set a “sector perform” rating for the company in a research note on Tuesday, November 7th. Finally, TheStreet downgraded Henry Schein from a “b” rating to a “c+” rating in a research note on Monday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. Henry Schein presently has a consensus rating of “Hold” and a consensus target price of $89.88.
TRADEMARK VIOLATION WARNING: “Jennison Associates LLC Buys 65,945 Shares of Henry Schein, Inc. (HSIC)” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://theolympiareport.com/2017/11/14/jennison-associates-llc-buys-65945-shares-of-henry-schein-inc-hsic.html.
Henry Schein, Inc. (NASDAQ HSIC) opened at $66.50 on Tuesday. Henry Schein, Inc. has a 52 week low of $65.72 and a 52 week high of $93.50. The company has a quick ratio of 0.86, a current ratio of 1.55 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $10,523.79, a price-to-earnings ratio of 18.81, a P/E/G ratio of 1.89 and a beta of 1.03.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.87 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by ($0.03). Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. The firm had revenue of $3.16 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same period in the prior year, the company posted $0.84 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. equities analysts predict that Henry Schein, Inc. will post 3.6 earnings per share for the current year.
Henry Schein announced that its Board of Directors has initiated a share repurchase program on Monday, September 18th that authorizes the company to repurchase $400.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 6.3% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.
In related news, SVP Paul Rose sold 2,126 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total value of $366,756.26. Following the completion of the transaction, the senior vice president now directly owns 17,841 shares of the company’s stock, valued at approximately $3,077,750.91. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.19% of the stock is currently owned by corporate insiders.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.